2020
DOI: 10.1038/s41586-020-2708-8
|View full text |Cite|
|
Sign up to set email alerts
|

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Abstract: Coronaviruses are prone to emergence into new host species most recently evidenced by SARS-CoV-2, the causative agent of the COVID-19 pandemic 1 . Small animal models that recapitulate SARS-CoV-2 disease are desperately needed to rapidly evaluate medical countermeasures (MCMs) 2 , 3 . SARS-CoV-2 cannot infect wildtype laboratory mice due to inefficient interactions between the viral spike (S) protein and the murine ortholog of the… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

32
609
0
3

Year Published

2020
2020
2022
2022

Publication Types

Select...
5
2
1

Relationship

2
6

Authors

Journals

citations
Cited by 562 publications
(644 citation statements)
references
References 50 publications
32
609
0
3
Order By: Relevance
“…Our mouse antibodies will not be applicable for use in clinical treatment, if not chimeric and humanized, due to their immunogenicity (Hansel et al, 2010; Reichert et al, 2005). On the other hand, they may be valuable for investigating the mechanism of immune responses to the virus during passive immunization using mouse models for SARS-CoV-2 infection (Bao et al, 2020; Dinnon et al, 2020; Hassan et al, 2020; Israelow et al, 2020; R. D. Jiang et al, 2020; Winkler et al, 2020). They could show stable performance due to lot-to-lot consistency and act as benchmarks for other antibodies and drug developments.…”
Section: Discussionmentioning
confidence: 99%
“…Our mouse antibodies will not be applicable for use in clinical treatment, if not chimeric and humanized, due to their immunogenicity (Hansel et al, 2010; Reichert et al, 2005). On the other hand, they may be valuable for investigating the mechanism of immune responses to the virus during passive immunization using mouse models for SARS-CoV-2 infection (Bao et al, 2020; Dinnon et al, 2020; Hassan et al, 2020; Israelow et al, 2020; R. D. Jiang et al, 2020; Winkler et al, 2020). They could show stable performance due to lot-to-lot consistency and act as benchmarks for other antibodies and drug developments.…”
Section: Discussionmentioning
confidence: 99%
“…1) (Corbett et al, 2020a;Zost et al, 2020). Inoculating these mice with Venezuelan equine encephalitis virus that expresses the SARS-CoV-2 Spike protein protected against SARS-CoV-2 infection, and neutralizing antibodies were inversely correlated with lung viral titers (Dinnon et al, 2020). Thus, mouse models are suitable for evaluating vaccine performance against viral replication in the lungs.…”
Section: Introductionmentioning
confidence: 99%
“…In contrast to golden Syrian hamsters and hACE2 transgenic mice, BALB/c and C57BL/6 mouse strains cannot be readily infected with SARS-CoV-2 human clinical isolates (Dinnon et al, 2020;Imai et al, 2020). Thus, wild-type mice require the modification of the SARS-CoV-2 receptor-binding domain to mediate productive infection and pathogenesis.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Animal models are useful in studying highly pathogenic human coronaviruses, the emergence potential of zoonotic coronaviruses, and to evaluate novel inhibitors for their ability to control coronavirus infection [4][5][6][7][8][9][10][11][12][13][14][15] . However, human coronaviruses do not replicate in mice without either extensive adaptation of the virus or genetic modi cation of the host by genetic editing of the receptor or by introducing the individual human receptor genes for each virus [4][5][6][7][8][9][10][11]14,15 . Although existing rodent models have made several important contributions to our understanding of coronavirus infection and pathogenesis, none of these models possess the diverse set of primary human cells present in the human lung that can serve as targets for viral infection 16 .…”
mentioning
confidence: 99%